Prem Lachman, M.D. has deep and broad experience in the pharma, biotech and financial industries. Thanks to the diverse experiences during his 35-year career – as a top-ranked pharmaceutical equity research analyst, a healthcare investor, and a physician – he has developed a differentiated perspective and skills, as well as acquired unique and valuable insights. Dr. Lachman has played a key role in M&A transactions and IPOs that exceed $50 Billion in value for pharmaceutical, biotech, Pharmacy Benefit Management companies and Contract Research Organizations. Throughout his career, he has extensively engaged with and advised the C-suites and Boards of pharma and biotech companies on strategy, business development, industry dynamics and capital markets. He has a strong and enduring network that includes current and former C-Suites of major pharma (Bristol Myers Squibb, AbbVie, Merck, Pfizer, GlaxoSmithKline), large-cap biotech (Amgen, Biogen, etc.), specialty pharma (Bausch + Lomb, Jazz Pharma, etc.) and CROs (ICON, PPD, etc.).

Dr. Lachman is the Founder, General Partner and Portfolio Manager for Maximus Capital, a healthcare hedge fund focused on pharmaceutical, biotechnology, medical device and managed care sectors. Prior to founding Maximus Capital, Dr. Lachman was co-portfolio manager for Galleon Group’s multi-billion dollar healthcare fund and Head of its Pharmaceutical Research. Prior to joining Galleon, he was Managing Director and Head of Global Healthcare Equity Research at Goldman Sachs, where he was responsible for investment research coverage of global pharmaceutical, specialty pharma and generics companies, as well as Contract Research Organizations. While at Goldman Sachs, Dr. Lachman was ranked #1 on Institutional Investor All-Star Research Team and Greenwich Surveys. He also coordinated Pharma and Biotech Investment Banking globally and played a key role in multi-billion dollar M&A deals and IPOs. Previously, he was Vice President of Equity Research at County Nat West USA and provided research coverage U.S. pharmaceuticals, generics and specialty pharmaceuticals companies. Prior to his career on Wall Street, Dr. Lachman was a general surgery resident at the LI Jewish Medical Center, where he co-authored a landmark study on the treatment of Crohn’s Disease.

Dr. Lachman is a Board Member for OPKO Health (OPKO) and is on its Investment, Compensation, Audit and Governance Committees. He is a Board Member at the Metropolitan Opera and a Director at the Museum of Modern Art.

He holds an M.D. from Mount Sinai School of Medicine and a Bachelor of Arts in Economics from Columbia University.